Inhibrx’s Ozekibart Shows Promise in Advanced Colorectal Cancer
Inhibrx Biosciences has unveiled encouraging interim data from its Phase 1/2 clinical trial evaluating Ozekibart in patients with advanced colorectal cancer. The biopharmaceutical company’s latest findings mark a significant milestone in the development of this novel biologic therapeutic candidate.
Inhibrx’s Ozekibart Shows Promise in Advanced Colorectal Cancer Read More »










